Open AccessKEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
Author(s) -
Amy L. Cummings,
Kate M. Santoso,
Jonathan W. Goldman
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.08.11
Subject(s) - pembrolizumab , ipilimumab , medicine , lung cancer , oncology , cancer , immunotherapy